Infinity Pharmaceuticals (DB:I3F) - Aandelenkoers, Nieuws & Analyse

I3F Overzicht aandelen

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. Meer informatie

I3F fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Risicoanalyse

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 14.5% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( €281K )

+ 2 meer risico's

Infinity Pharmaceuticals, Inc. Concurrenten

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Paion

DB:PA8K

€42.8k

co.don

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Infinity Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$0.017
52 Week Hoogtepunt	US$0.69
52 Week Laag	US$0.011
Bèta	1.64
11 maand verandering	0%
3 maanden verandering	3.64%
1 Jaar Verandering	-96.42%
33 jaar verandering	-99.01%
5 jaar verandering	-98.15%
Verandering sinds IPO	-99.40%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	I3F	DE Biotechs	DE Markt
7D	0%	-1.1%	1.1%
1Y	-96.4%	-18.8%	7.2%

Rendement versus industrie: I3F presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -18.8 % opleverde.

Rendement versus markt: I3F presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.2 % opleverde.

Prijsvolatiliteit

Is I3F's price volatile compared to industry and market?
I3F volatility
I3F Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van I3F is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van I3F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	30	Seth Tasker	www.infi.com

Infinity Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Infinity Pharmaceuticals zich tot de beurswaarde?
I3F fundamentele statistieken
Marktkapitalisatie	€256.32k
Inkomsten(TTM)	-€37.30m
Inkomsten(TTM)	€2.34m

0.1x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is I3F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
I3F resultatenrekening (TTM)
Inkomsten	US$2.57m
Kosten van inkomsten	US$28.53m
Brutowinst	-US$25.96m
Overige uitgaven	US$14.99m
Inkomsten	-US$40.95m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.45
Brutomarge	-1,010.35%
Nettowinstmarge	-1,593.93%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde I3F op de lange termijn?

Bekijk historische prestaties en vergelijking

I3F Overzicht aandelen

Risicoanalyse

Infinity Pharmaceuticals, Inc. Concurrenten

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

DB:PA8K

€42.8k

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.50 loss per share (vs US$0.53 loss in FY 2021)

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2021)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021)

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 1Q 2021)

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings released: US$0.53 loss per share (vs US$0.68 loss in FY 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: €4.00

New 90-day high: €2.00

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

New 90-day high: €1.95

New 90-day high: €1.45

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - €1.03

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Infinity Pharmaceuticals, Inc. Samenvatting

0.1x

0.0x

Inkomsten en omzet